Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

Abstract #7083; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

An oral dosage formulation of azacitidine: A pilot pharmacokinetic study - R. Ward, Pharmion; Abstract #7084; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

Response to azacitidine in patients with myelodysplastic syndrome with marrow fibrosis - R. Juvvadi, Western Penn, Pennsylvania; Abstract #7089; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

(Back to top)

Contact details

Breanna Burkart or Anna Sussman

Directors, Investor Relations and Corporate Communications

Pharmion Corporation

Tel: +1 720 564 9144 or +1 720 564 9143

Tara May

On-site media contact

Tel: +1 303 646 7832

About Vidaza

On May 19, 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes, which include both low-risk and high-risk patients. These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including can
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:9/17/2014)... Sept. 17, 2014   OTEMR, Inc. , ONETOUCH ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  ONETOUCH EMR 2.0 was certified on July 14, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
(Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer from ... disease. Recently the FDA approved the launch ... an innovative implant device developed by Spinal Kinetics, which may ... neck and or arm pain. Hospital for Special Surgery (HSS), ... only hospital in New York City ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014   ... data analytics solution that brings complete visibility to ... risks in an ever-evolving reimbursement landscape. Powered by ... brings transparency to the critical point between patient ... impact revenue. The solution will improve revenue capture, ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... SPRING, Md., Nov. 23, 2011 The FDA today ... owner for substituting ingredients and products without noting the ... filed on behalf of the FDA by the U.S. ... and distributing more than 400 products for being in ...
... 23, 2011 /PRNewswire-iReach/ -- Now in its 13th ... discuss, investigate, and learn about the latest in pharmaceutical technology. ... at the Crocus Expo, International Exhibition Centre, in Moscow. ... sustainable air filters — a key ...
Cached Medicine Technology:FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 2FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 3Camfil Farr to Discuss Sustainable Air Filtration at PHARMTECH 2011 2Camfil Farr to Discuss Sustainable Air Filtration at PHARMTECH 2011 3
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
(Date:9/17/2014)... New York (PRWEB) September 17, 2014 ... involving the Conserve line of metal-on-metal hip replacements ... underway in U.S. District Court, Northern District of ... updated Case List issued by the U.S. Judicial ... at least 397 product liability claims have been ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Smart Flour ... Picks by Progressive Grocer, a leading trade magazine targeted ... awarded for originality and flavor, among other attributes. Smart ... an Editor’s Pick in the September print issue of ... website. , The pizza won based on its superior ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
Breaking Medicine News(10 mins):Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
... Month, BETHESDA, Md., Jan. 3 AABB (formerly ... individuals,participating in the presidential elections to continue making an ... the month of,January, National Blood Donor Month (NBDM) provides ... give blood at a time of the year when,it ...
... ... Refractory Patients to Replace Current TIME-2 ... Trial ... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced that the Tanespimycin in,Myeloma Evaluation or TIME-1 pivotal Phase ...
... young people,s blood sugar levels, study finds , THURSDAY, Jan. ... three nights running has the same negative effect on the ... pounds, diabetes researchers report. , In fact, young adults ... their risk of type 2 diabetes, according to a study ...
... others with a family history of ... glaucoma are particularly vulnerable, SAN FRANCISCO, Jan. 3 ... do not notice as their peripheral,vision diminishes or blind spots occur. ... disease are unaware of their condition.,January is Glaucoma Awareness Month, and ...
... Abbott (NYSE: ABT ),will announce its financial results ... on Wednesday, Jan. 23, 2008, before the market opens., ... webcast of the earnings,conference call at 8 a.m. Central ... Investor Relations Web site at, http://www.abbottinvestor.com . An archived ...
... the story is the same: New,Year,s resolutions made, New ... be combined with online health tools and expert advice,to ... growing health,properties on the Internet -- launched "Resolutions 2.0," ... video from Revolution Health at:, http://media.medialink.com/WebNR.aspx?story=34279 ) "Resolutions ...
Cached Medicine News:Health News:Exercise Your Right to Vote and Continue to Make a Difference by Giving Blood in 2008 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 3Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 4Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 5Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 6Health News:Lack of Deep Sleep Raises Diabetes Risk 2Health News:Lack of Deep Sleep Raises Diabetes Risk 3Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches 'Resolutions 2.0' 2
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
Medicine Products: